Skip to content
DataLookout
Menu

NCT07024563

Study of Ravulizumab in Pediatric Participants With Primary IgAN

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 8 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 22 words
    • Trial sites expanded: 15 → 19 locations
    • Secondary endpoints: details revised at 1 of 11 entries
    • Publications: 1 to 2
  2. Notable Enrollment increased: 24 → 36 participantsv9 Show 4 more changesShow less
    • Eligibility criteria revised
    • Primary completion pushed from Jul 12, 2028 to Nov 29, 2028
    • Study completion pushed from Nov 27, 2029 to Apr 19, 2030
    • Study sites: 14 to 15
  3. Minor Study sites: 13 to 14v8
  4. Notable Eligibility criteria expanded, about 76 words
    • Primary endpoints: 3 to 1
    • Enrollment target: 18 to 24
    • Secondary endpoints: 8 to 11
    v7
  5. Notable Primary completion date: Jul 7, 2027 to Jul 12, 2028
    • Study sites: 12 to 13
    • Study completion date: Nov 23, 2028 to Nov 27, 2029
    v6
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Primary completion date: Oct 20, 2027 to Jul 7, 2027
    • Study completion date: Mar 8, 2029 to Nov 23, 2028
    • Site details revised at 7 of 12 sites
    v5
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 26, 2025 to Jun 14, 2025
    • Site details revised at 12 of 12 sites
    v4
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from Baseline in Proteinuria Based on Urine Protein to Creatinine Ratio (UPCR) at Week 34
Timeframe: Baseline, Week 34

Secondary (11)

Maximum Observed Plasma Concentration (Cmax) of Ravulizumab
Trough Serum Concentration (Ctrough) of Ravulizumab
Change From Baseline in Serum Free Complement Component 5 (C5) Concentration
Change from Baseline in proteinuria based on Urine Protein to Creatinine Ratio (UPCR) at Week 10
Change from Baseline in Albuminuria based on Urine Albumin to Creatinine Ratio (UACR) at Week 34
Show 6 moreShow less
Number of Participants with Partial Remission
Annualized Total Estimated Glomerular Filtraion Rate (eGFR) over 106 weeks
Change from Baseline in eGFR
Number of Participants with UPCR <0.5 gram of protein per gram of creatinine
Number of Participants With Treatment Emergent Adverse Events, Treatment Emergent Serious Adverse Events and Adverse Events of Special Interest
Number of Participants with Antidrug Antibodies to Ravulizumab and Neutralizing Antibodies

Arms and interventions

RavulizumabExperimental

All participants will receive a weight-based loading dose of ravulizumab on Day 1, followed by weight-based maintenance treatment with ravulizumab on Day 15 and either once every 8 weeks (q8w) thereafter or once every 4 weeks (q4w) depending on weight.

Drugs: Ravulizumab

Sites

19 sites in 9 countries

Spain 4, Italy 3, Canada 2, China 2, Germany 2, Taiwan 2, United States 2, Japan 1, South Korea 1